Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

Critical Reviews in Oncology/Hematology

Volumn 100, Issue , 2016, Pages 99-106

  Giampieri, Riccardo ^a   Caporale, Marta ^b   Pietrantonio, Filippo ^b   De Braud, Filippo ^b   Negri, Francesca V ^c   Giuliani, Francesco ^d   Pusceddu, Valeria ^e   Demurtas, Laura ^e   Restivo, Angelo ^e   Fontanella, Caterina ^f   Aprile, Giuseppe ^f   Cascinu, Stefano ^a   Scartozzi, Mario ^e  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e DEPARTMENT OF RADIOLOGY   (Italy)

^f UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Aflibercept; Angiogenesis; Bevacizumab; Colorectal cancer; Ramucirumab; Second line

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; HOMEOSTASIS; HUMAN; METASTATIC COLORECTAL CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THERAPY EFFECT; ADJUVANT CHEMOTHERAPY; COLORECTAL NEOPLASMS; METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BEVACIZUMAB; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 84960452031     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.02.005     Document Type: Review

References (50)

1. Bach P.B. Ramucirumab for colon cancer and the problem of rising prices independent of benefits. Oncologist 2015, 20:1-2.
2. Bagri A., Berry L., Gunter B., et al. Effects of anti-VEGF treatment duration on tumour growth, tumour regrowth, and treatment efficacy. Clin. Cancer Res. 2010, 16:3887-3900.
3. Banfalvi G. Homeostasis-Tumour-Metastasis 2014, Springer Science. 10.1007/978-94-007-7335-6_1.
4. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumour vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
5. Bendell J.C., Bekaii-Saab T.S., Cohn A.L., et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIE, a bevacizumab observational cohort study. Oncologist 2012, 17:1486-1495.
6. Bennouna J., Sastre J., Arnold D., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013, 14:29-37.
7. Berges G., Benjamin L.E. Tumourigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
8. Bieche I., Vacher S., Vallerand D., Richon S., Hatem R., De Plater L., Dahmani A., Némati F., Angevin E., Marangoni E., Roman-Roman S., Decaudin D., Dangles-Marie V. Vasculature analysis of patient derived tumour xenografts using species-specific PCR assays: evidence of tumour endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC Cancer 2014, 14(March):178. (PubMed PMID: 24625025; PubMed Central PMCID: PMC4007753). 10.1186/1471-2407-14-178.
9. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009, 2:re1.
10. Chiron M.V.P., Lejeune P., Demers B., Leopold D., Bissery M.C. Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumour models. Proc. from the AACR-NCI-EORTC: Mol Targets and Cancer Therapeutics 2007, (Abstract A13).
11. Del Prete M., Giampieri R., Loupakis F., Prochilo T., Salvatore L., Faloppi L., Bianconi M., Bittoni A., Aprile G., Zaniboni A., Falcone A., Scartozzi M., Cascinu S. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget 2015, 6:33982-33992. ([Epub ahead of print] PubMed PMID: 26334693.).
12. Faloppi L., Scartozzi M., Bianconi M., Svegliati Baroni G., Toniutto P., Giampieri R., Del Prete M., De Minicis S., Bitetto D., Loretelli C., D'Anzeo M., Benedetti A., Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer 2014, 14(February):110. (PubMed PMID: 24552144;PubMed Central PMCID: PMC3930857.). 10.1186/1471-2407-14-110.
13. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumours without affecting healthy vessels. Cell 2007, 131:463-475.
14. Fontanella C., Ongaro E., Bonzonello S., et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann. Transl. Med. 2014, 2(12):123.
15. Fuchs C.S., Tomasek J., Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomized, multicentre, placebo-controlled phase 3 trial. Lancet 2014, 383:31-39.
16. Garon E.B., Ciuleanu T.-E., Arrieta O., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384:665-673.
17. Gaya A., Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat. Rev. 2012, 38:484-493.
18. Giampieri R., Scartozzi M., Del Prete M., Fulli A., Faloppi L., Bianconi M., Maccaroni E., Cascinu S. The angiogenetic ladder, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat. Rev. 2014, 40(September (8)):934-941. (Epub 2014 Jun 20. PubMed PMID: 24997679.). 10.1016/j.ctrv.2014.06.004.
19. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 25:1539-1544.
20. Giantonio B.J. Targetedtherapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat. Rev. Clin. Oncol. 2009, 6:311-312.
21. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 2008, 26:5326-5334.
22. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., et al. VEGF-trap: a VEGF blocker with potent antitumour effects. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11393-11398.
23. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., Jaffe R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumour and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 2005, 11:6966-6971.
24. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. NEJM 2004, 350(23):2335-2342.
25. Iwamoto S., Takahashi T., Tamagawa H., et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann. Oncol. 2015, 26:1427-1433.
26. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., Adinin R., Overman M.J., Valero V., Wen S., Lieu C., Yan S., Tran H.T., Ellis L.M., Abbruzzese J.L., Heymach J.V. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28(January (3)):453-459. (Epub 2009 Dec 14). 10.1200/JCO.2009.24.8252.
27. Kubicka S., Greil R., André T., et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann. Oncol. 2013, 24:2342-2349.
28. Masi G., Salvatore L., Boni L., et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann. Oncol. 2015, 26:724-730.
29. Mesange P., Poindesseous V., Sabbah M., et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 2013, 5(October (13)):4709-4720.
30. Miyazaki S., Kikuchi H., Iino I., Uehara T., Setoguchi T., Fujita T., Hiramatsu Y., Ohta M., Kamiya K., Kitagawa K., Kitagawa M., Baba S., Konno H. Anti-VEGF antibody therapy induces tumour hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int. J. Cancer 2014, 135(July (2)):295-307. (Epub 2014 Jan 6). 10.1002/ijc.28686.
31. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:16-24.
32. Pericay C.F.G., Saunders M., Thomas A., Roh J.K., Lopez R., et al. Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM): Abstract O-0024. Ann. Oncol. 2012, 23(Suppl. 4):iv5-18.
33. Rudge J.S., Holash J., Hylton D., Russell M., Jiang S., Leidich R., et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18363-18370.
34. Scartozzi M., Giampieri R., Maccaroni E., Del Prete M., Faloppi L., Bianconi M., Galizia E., Loretelli C., Belvederesi L., Bittoni A., Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br. J. Cancer 2012, 106(February (5)):799-804. (Epub 2012 Feb 7. PubMed PMID: 22315053; PubMed Central PMCID: PMC3305976.). 10.1038/bjc.2012.17.
35. Scartozzi M., Faloppi L., Bianconi M., Giampieri R., Maccaroni E., Bittoni A., Del Prete M., Loretelli C., Belvederesi L., Svegliati Baroni G., Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One 2012, 7(3):e32653. (Epub 2012 Mar 26. PubMed PMID: 22461886; PubMedCentral PMCID: PMC3312882.). 10.1371/journal.pone.0032653.
36. Silvestris N., Scartozzi M., Graziano G., Santini D., Lorusso V., Maiello E., Barni S., Cinieri S., Loupakis F., Pisconti S., Brunetti A.E., Palasciano G., Palmieri V.O., Del Prete M., Dell'Aquila E., Latiano T.P., Petrelli F., Lutrino S., Rossini D., Giampieri R., Lotesoriere C., Cascinu S. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin. Biol. Ther. 2015, 15(February (2)):155-162. (Epub 2014 Nov 19. PubMed PMID: 25411089.). 10.1517/14712598.2015.986452.
37. Sitohy B., Nagy J.A., Dvorak H.F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012, 72(April (8)):1909-1914. (Review.PubMedPMID:22508695;PubMedCentralPMCID:PMC3335750). 10.1158/0008-5472.CAN-11-3406.
38. Spratlin J. Ramucirumab (IMC-1121B) monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep. 2011, 13(2):97-102.
39. Tabernero J., Van Cutsem E., Lakomy R., Prausová J., Ruff P., van Hazel G.A., et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur. J. Cancer 2014, 50:320-331.
40. Tabernero J., Yoshino T., Cohn A.L., et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015, 16(5):499-508.
41. Tang P., Cohen S.J., Kollmannsberger C., Bjarnason G., Virik K., Mackenzie M.J., et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin. Cancer Res. 2012, 18:6023-6031.
42. Tomida C., Yamagishi N., Aibara K., Yano C., Uchida T., Abe T., Ohno A., Hirasaka K., Nikawa T., Teshima-Kondo S. Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells. J. Med. Invest. 2015, 62(1-2):75-79. (PubMedPMID:25817288). 10.2152/jmi.62.75.
43. Tonra J.R., Deevi D.S., Corcoran E., et al. Synergistic antitumour effect of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 2006, 12:2197-2207.
44. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012, 30:3499-3506.
45. Van Cutsem E., Khayat D., Verslype C., Billemont B., Tejpar S., Meric J.B., et al. Phase I Dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur. J. Cancer 2013, 49:17-24.
46. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
47. Wilke H., Muro K., van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized, phase 3 trial. Lancet Oncol. 2014, 15:1224-1235.
48. Xu J., Wang J., Xu B., Ge H., Zhou X., Fang J.Y. Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria. Mol. Cancer Ther. 2013, 12(May (5)):717-724. (MCT-12-1016-T. Epub 2013 Feb 20. PubMed PMID: 23427299.). 10.1158/1535-7163.
49. Yang Yoon Jung, Choi Joon-Seok, Choi Jin Woo Antiangiogenic therapy impedes infiltration by CD4+ and CD8+ cells into an early colon tumour. J. Cancer Prev. 2015, 20:129-135.
50. Yao J., Wu X., Kasman I.M., Vogt T., Phan V., Shibuya M., et al. Expression of a functional VEGFR-1 in tumour cells is a major determinant of anti-PlGF antibodies efficacy. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11590-11595.